Evaluation of the use of additional capabilities of immunochemiluminescent analysis for determining the duration of infection with human immunodeficiency virus
https://doi.org/10.22625/2072-6732-2024-16-3-105-111
Abstract
Early assessment of HIV incidence is an important public health tool for understanding the state of the epidemic in a particular area, identifying high-risk groups, and assessing the effectiveness of HIV prevention interventions.
Objective. To assess the possibility of using the positivity rate (S/CO) in the HIV Ag/Ab immunoassay on the Alinity i analytical platform to determine the duration of infection during HIV screening.
Materials and methods. The study included 316 HIV-infected patients with different infection durations. Immunochemical analysis was performed on an Alinity i automatic analyzer (Abbott Laboratories, USA) using the Alinity i HIV Ag/Ab Reagent Kit (Abbott Laboratories, Germany) in accordance with the manufacturer’s instructions.
Results. Statistical analysis of 316 blood samples from HIV-infected patients at different stages of infection demonstrated the reactivity of the Alinity i HIV Ag/Ab test result and a dynamic increase in the positivity ratio during the first six months after the onset of the disease. Based on the data obtained, a threshold value (≤294 conventional units) was obtained for the positivity ratio, which allowed for a clear distinction between HIV-positive patients with a recent (<6 months) period of infection. At the same time, the sensitivity and specificity indicators for detecting recent infection in the CMIA analysis were 79,0% and 63,2%, respectively.
Conclusion. The additional usage of the positivity ratio in the Alinity i HIV Ag/Ab CMIA analysis meets the acceptability criteria for assessing the duration of HIV infection and can be a useful tool for analyzing the stage of the epidemic in a particular territory.
About the Authors
A. I. Ermakov
Saint-Petersburg Center for the Prevention and Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
Saint-Petersburg
N. N. Kotova
Saint-Petersburg Center for the Prevention and Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
Saint-Petersburg
T. N. Vinogradova
Saint-Petersburg Center for the Prevention and Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
Saint-Petersburg
D. E. Kireev
Central Research Institute of Epidemiology
Russian Federation
Russian Federation
Moscow
References
1. Brookmeyer, R, Quinn, TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. American Journal of Epidemiology 1995; 141: 166–172.Google Scholar
2. Busch, MP, et al. Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 2010; 24: 2763–2771. Google Scholar
3. Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med. 2001;134:25-29.
4. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352:1873-1883.
5. Daar ES, Moudgil T, Meyer RD, et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324:961-964.
6. Pilcher CD, Shugars DC, Fiscus SA, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS. 2001;15:837-845.
7. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
8. Pilcher CD, McPherson JT, Leone PA, et al. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA. 2002;288:216-221.
9. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infection: updated recommendations. http://stacks.cdc.gov/view/cdc/23447. Accessed July 3, 2014.
10. Branson BM. The future of HIV testing . J Acquir Immune Defic Syndr. 2010;55(suppl 2):S102-S105.
11. Hutchinson AB, Patel P, Sansom SL, et al. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of 3 public health settings . PLoS Med. 2010;7(9):e1000342.
12. Murphy G., Parry J.V. Assay for the detection of recent infections with human immunodeficiency virus type 1. Eurosurveillance. 2008; 13 (36–4): 4–10.
13. Kassanjee R., Pilcher C., Keating S., Facente S., McKinney E., Price M. et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS. 2014; 28 (16): 2439–49.
14. Duong Y.T., Qiu M., De A.K., Jackson K., Dobbs T., Kim A.A. et al. Detection of recent HIV-1 infection using a new limiting antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One. 2012; 7 (3): e33328.
15. Curtis K.A., Hanson D.L., Kennedy M.S., Owen S.M. Evaluation of a multiplex assay for estimation of HIV-1 incidence. PLoS One. 2013; 8 (5): e64201.
16. Ly, T. D., L. Martin, D. Daghfal, A. Sandridge, D. West, R. Bristow, L. Chalouas, X. Qiu, S. C. Lou, J. C. Hunt, G. Schochetman, and S. G. Devare. 2001. Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection. J. Clin. Microbiol.39:3122-3128.
17. Speers, D., P. Phillips, and J. Dyer. 2005. Combination assay detecting both human immunodeficiency virus (HIV) p24 antigen and anti-HIV antibodies opens a second diagnostic window. J. Clin. Microbiol.43:5397-5399.
18. Weber, B., E. H. Fall, A. Berger, and H. W. Doerr. 1998. Reduction of diagnostic window by new fourth-generation human immunodeficiency virus screening assays. J. Clin. Microbiol.36:2235-2239.
19. Ramos EM, Harb S, Dragavon J, Swenson P, Stekler JD, Coombs RW. Performance of an alternative HIV diagnostic algorithm using the ARCHITECT HIV Ag/Ab Combo assay and potential utility of sample-to-cutoff ratio to discriminate primary from established infection. J Clin Virol. 2013;58 Suppl 1:e38–43. pmid:24029686.
20. Grebe E, Welte A, Hall J, Keating SM, Facente SN, Marson K, et al. Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms. J Acquir Immune Defic Syndr. 2017;76(5):547–55. Epub 2017/09/16. pmid:28914669.
21. Ramos, Eric & Ortega, José & Daza, Glenda & Namkung, Yuree & Harb, Socorro & Dragavon, Joan & Coombs, Robert. (2015). Use of the Sample-to-Cutoff Ratio (S/CO) to Identify Recency of HIV-1 Infection. 10.13140/RG.2.2.32369.07529.
22. Westheimer E, Fu J, Radix A, et al. An HIV-1 RNA test following a reactive fourth-generation antigen/antibody combination assay confirms a high proportion of HIV infections . J Clin Virol. 2014;61(4):623-624.
23. Huang J, Wang M, Huang C, Liang B, Jiang J, Ning C, Zang N, Chen H, Liu J, Chen R, Liao Y, Ye L, Liang H. Western Blot-Based Logistic Regression Model for the Identification of Recent HIV-1 Infection: A Promising HIV-1 Surveillance Approach for Resource-Limited Regions. Biomed Res Int. 2018 Jan 14;2018:4390318. doi: 10.1155/2018/4390318. PMID: 29568753; PMCID: PMC5820577.
24. Murzakova A.V., Kireev D.E. Sovremennye metody vyyavleniya sluchaev nedavnej infekcii, vyzvannoj virusom immunodeficita cheloveka. Epidemiol. infekc. bolezni. Aktual. vopr. 2020; 10(3): 116–22 DOI: https://dx.doi.org/10.18565/epidem.2020.10.3.116–22.
Review
For citations:
Ermakov A.I., Kotova N.N., Vinogradova T.N., Kireev D.E. Evaluation of the use of additional capabilities of immunochemiluminescent analysis for determining the duration of infection with human immunodeficiency virus. Journal Infectology. 2024;16(3):105-111. (In Russ.) https://doi.org/10.22625/2072-6732-2024-16-3-105-111
Views:
221
.png)
.png)
Email this article 